Status:

NOT_YET_RECRUITING

Analgesic Effect of TENS-WAA Combined With Tramadol Hydrochloride During Oocyte Retrieval Surgery

Lead Sponsor:

First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University

Conditions:

Oocyte Retrieval for IVF

Pain

Eligibility:

FEMALE

21-42 years

Phase:

NA

Brief Summary

This study is a single-centre randomised controlled trial. It aimed to evaluate the efficacy and safety of transcutaneous electrical nerve stimulation based on wrist-ankle acupuncture theory(TENS-WAA)...

Eligibility Criteria

Inclusion

  • Females aged between 21 and 42 years.
  • Patients diagnosed with infertility requiring oocyte retrieval for in vitro fertilisation-embryo transfer.
  • Body Mass Index (BMI) 18.5 ≤ BMI ≤ 29.9 kg/m².
  • Regular menstrual cycles with ultrasound monitoring demonstrating dominant follicle development and ovulation during the natural cycle; good ovarian reserve: follicle-stimulating hormone (FSH) \< 10 IU/L, antral follicle count (AFC) \> 6, anti-Müllerian hormone (AMH) \> 1.5 ng/ml.
  • Undergoing ovarian stimulation therapy using follicle-stimulating hormone (FSH) or gonadotropin protocols.
  • Electing tramadol hydrochloride injection for analgesia during oocyte retrieval.
  • Voluntary participation with signed written informed consent.

Exclusion

  • History of other chronic pain conditions, or prolonged use of opioid medications, history of anaesthetic drug addiction, or chronic alcohol abuse.
  • Severe pelvic adhesions.
  • Presence of pacemakers or other implanted medical electronic devices.
  • Concurrent use of high-frequency surgical equipment, artificial heart-lung machines, medical shortwave therapy, or microwave therapy devices.
  • Presence of scarring or skin lesions at electrode application sites.
  • Severe anxiety, depression, or other psychiatric conditions impairing accurate description of sensations, or any other disorders potentially affecting pain perception.
  • Conditions contraindicating or affecting oocyte retrieval, such as coagulation disorders, acute pelvic inflammation, vaginitis, trichomoniasis, endometriomas, ovarian cysts.
  • Individuals with laparoscopically and/or ultrasonographically confirmed endometriosis.
  • Patients with ovarian hyporesponsiveness following conventional ovarian stimulation medication.

Key Trial Info

Start Date :

November 8 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2026

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT07212127

Start Date

November 8 2025

End Date

December 31 2026

Last Update

October 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Affiliated Hospital of Naval Medical University

Shanghai, Shanghai Municipality, China, 200433